Citadel Advisors
IEIH

Citadel Advisors’s iShares Evolved U.S. Innovative Healthcare ETF IEIH Stock Holding History

Citadel Advisors’s Portfolio IEIH Stock Details IEIH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,493
Closed -$740K – 14216
2022
Q2 		$740K Buy
22,493
+6,571
+41% +$216K ﹤0.01% 7729
2022
Q1 		$545K Sell
15,922
-676
-4% -$22.4K ﹤0.01% 9184
2021
Q4 		$589K Buy
16,598
+458
+3% +$16K ﹤0.01% 9285
2021
Q3 		$567K Buy
+16,140
New +$585K ﹤0.01% 9571

Citadel Advisors's IEIH Position: Q3 2022 in Review

Citadel Advisors sold out of iShares Evolved U.S. Innovative Healthcare ETF (IEIH) in Q3 2022, closing a stake of 22,493 shares — an estimated $740K sold.

Citadel Advisors first reported a position in IEIH in Q3 2021 and held it in 4 quarters. The position peaked at $740K in Q2 2022. 0 funds tracked by Wall St. Rank hold IEIH as of Q3 2022.

  • Citadel Advisors reported no remaining iShares Evolved U.S. Innovative Healthcare ETF position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 22,493 iShares Evolved U.S. Innovative Healthcare ETF shares in Q3 2022, an estimated $740K.
  • Citadel Advisors first reported a position in iShares Evolved U.S. Innovative Healthcare ETF in Q3 2021 and held it in 4 quarters.
  • Citadel Advisors's iShares Evolved U.S. Innovative Healthcare ETF position peaked at $740K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held iShares Evolved U.S. Innovative Healthcare ETF as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.